Skip to Main Content

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the gloomy skies hovering overhead. After all, as the Morning Mayor used to say, “Every brand new day should be unwrapped like a precious gift.” While you contemplate the possibilities and tug on the ribbon just a little, we will fire up the coffee kettle and make yet another cup of stimulation as we set about our journey. As always, you are welcome to join us. Meanwhile, here are a few items of interest to help you along. Hope you have a productive day and do keep in touch …

The European Medicines Agency updated its assessment of risk from valsartan medicines containing NDMA, a substance linked to cancer, after examining test results from supplies made by Zhejiang Huahai. The agency estimates the risk to be about 1 in 5,000 for an adult who had taken a medicine at the highest dose — 320 mg — every day from July 2012 to July 2018, which is line with previous calculations. To some extent, the estimate is supported by a Danish study that tracked patients who had taken medicines containing valsartan from Zhejiang Huahai over the past six years.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!